Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients

Deng, Kui; Yang, Chunyan; Tan, Qilong; Song, Wei; Lu, Ming-Liang; Zhao, Weiwei; Lou, Ge; Li, Zhenzi; Li, Kang; Hou, Yan

doi:10.1016/j.ygyno.2018.06.022

Cited by 123 publications

(135 citation statements)

References 12 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…1 The management of liver metastases still represents a limit for a complete surgical treatment; few reports agree that liver resection as part of cytoreductive surgery for ovarian cancer is safe and may offer survival benefits. [1][2][3]5,6,8 However, a 2015 report stated that liver resection in these patients was associated with lifethreatening complications and impaired liver function, 11 and some researchers have questioned the benefits of surgical management of non-colorectal, nonneuroendocrine liver metastasis. 5,8 The average ages of the patients with parenchymal and peritoneal seeding metastasis were 47 and 45 years, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Minor liver resections were the most-frequently performed operations in the current series; similar results were found by other researchers. 1,3,15 In contrast, anatomical liver resections seem to have a small role in the management of advanced ovarian cancer; however, this is yet to be established. A free liverresection margin does not seem to influence the outcome of these particular patients according to the concept of optimal cytoreduction for ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

“…It is known that patients with advanced ovarian cancer, regardless of the site of metastasis have poor prognoses. 3 Winter et al reported that hepatic parenchymal metastases represent 18% of these cancers and were the second most-frequent cause of stage IV disease. 4 In addition, another study showed that liver metastases were found in up to 50% of patients who died from ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

“…Cytoreduction, followed by platinum-based chemotherapy, is the current standard treatment for ovarian cancer. 3,5 A systematic meta-analysis showed that with every 10% increase in optimal cytoreduction, there is a 5.5% increase in survival. 5 In this context, some studies have explored the implementation of upper abdominal surgery to achieve complete macroscopic debulking.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer

Luna‐Abanto

Ruiz

Martínez

et al. 2020

Journal of Gynecologic Surgery

View full text Add to dashboard Cite

Objective: The aim of this study was to describe and evaluate the safety of hepatic resections for ovarian cancer liver metastases and the benefit in terms of survival as part of cytoreductive surgery among peritoneal seeding and parenchymal metastases. Materials and Methods: Data were reviewed retrospectively from patients who underwent liver resection as part of cytoreductive surgery for ovarian cancer at the Instituto Nacional de Enfermedades Neoplásicas, in Lima, Perú, patients underwent surgical cytoreduction for ovarian cancer; 39 of these patients had liver resection as part of their surgical treatment, with 9, 17, and 13 patients receiving primary, secondary, and tertiary, resections, respectively. The mean age of the patients was 46, the majority (87%) had stage III/IV ovarian cancer. In addition, 21 patients had parenchymal metastasis resections, and 95% of the patients had Dindo-Clavien I and II grade complications. The 30-day mortality rate was 0. Conclusions: Liver resection for advanced ovarian cancer is a safe procedure for primary up to quaternary cytoreduction and may confer survival benefits to patients. ( J GYNECOL SURG 36:70)

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer

Luna‐Abanto

Ruiz

Martínez

et al. 2020

Journal of Gynecologic Surgery

View full text Add to dashboard Cite

show abstract

“…Peritoneal cavity is the most common EOC site of progression, but haematogenous spreading may occur too (2), involving liver, distant lymph nodes, pleura, lungs and, less frequently, skin and bone (3,4). Central nervous system (CNS) is a rare localization of disease, with a reported incidence ranging between 0,3 and 12% (4,5). Recently, brain involvement seems to increase (6), probably due to improvement of medical treatments, radiotherapy and surgery (3,(7)(8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers

Mittica¹,

Goia

Gambino

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Central nervous system (CNS) spreading from epithelial ovarian carcinoma (EOC) is an uncommon but increasing phenomenon. We previously reported in a small series of 11 patients a correlation between Androgen Receptor (AR) loss and localization to CNS. Aims of this study were: to confirm a predictive role of AR loss in an independent validation cohort; to evaluate if AR status impacts on EOC survival. Results We collected an additional 29 cases and 19 controls as validation cohort. In this independent cohort at univariate analysis, cases exhibited lower expression of AR, considered both as continuous (p<0.001) and as discrete variable (10% cut-off: p<0.003; Immunoreactive score: p<0.001). AR negative EOC showed an odds ratio (OR) = 8.33 for CNS dissemination compared with AR positive EOC. Kaplan-Meier curves of the combined dataset, combining data of new validation cohort with the previously published cohort, showed that AR<10% significantly correlates with worse outcomes (p=0.005 for Progression Free Survival (PFS) and p=0.002 for brain PFS (bPFS) respectively). Comparison of AR expression between primary tissue and paired brain metastases in the combined dataset did not show any statistically significant difference. Conclusions We confirmed AR loss as predictive role for CNS involvement from EOC in an independent cohort of cases and controls. Early assessment of AR status could improve clinical management and patients’ prognosis.

show abstract